辅助放疗改善新辅助化疗后持续N2病变的IIIA(N2)期非小细胞肺癌生存
基于美国国家癌症数据库2004至2017年1855例完全切除、接受新辅助多药化疗的临床III(N2)期非小细胞肺癌患者,回顾性分析辅助放疗(45 Gy及以上 vs 无)与总生存的关系。持续N2组辅助放疗在单因素、多因素及倾向性评分匹配分析中均与总生存改善相关,而降期组无显著获益。
要点
- 持续N2组辅助放疗与总生存改善相关(单因素P=0.004,多因素P=0.028,倾向性评分匹配P=0.0347)。
- 降期至pN0-1组辅助放疗对总生存无显著获益(单因素P=0.077)。
- 全体队列中辅助放疗对总生存无显著影响(单因素P=0.27)。
核心结论
- 这项大规模回顾性分析提示,辅助放疗可能在新辅助化疗后持续N2病变中仍有一定作用,需进一步研究。
研究设计与样本
- 回顾性分析美国国家癌症数据库2004年至2017年诊断为临床III(N2)期非小细胞肺癌的患者。
- 纳入标准包括完全切除(R0)、病理诊断、新辅助多药化疗、术后N2状态信息(持续N2 vs 降期至pN0-1)、辅助放疗(45 Gy及以上 vs 无)及美国癌症联合委员会分期版本(第6版 vs 第7版)。
- 排除接受任何剂量新辅助放疗或辅助放疗总剂量低于45 Gy者。
- 共1855例符合标准,持续N2组854例,降期组1001例。
- 采用Kaplan-Meier法和log-rank检验进行生存分析,倾向性评分匹配分析用于验证,所有统计分析为双侧,P<0.05为统计学显著。
主要发现
- 全体队列中持续N2组(854例,中位生存50.7个月)与降期组(1001例,中位生存82.7个月)总生存差异显著。
- 辅助放疗在全体队列和降期组中显示非显著的生存不利影响(单因素P值分别为0.27和0.077)。
- 持续N2组中,辅助放疗在单因素和多因素分析中均显示总生存显著改善(P分别为0.004和0.028)。
- 倾向性评分匹配分析验证了持续N2组的上述发现(P=0.0347)。
临床怎么用
- 原文结论认为辅助放疗可能在新辅助化疗后持续N2病变中仍有一定作用,需进一步研究。
局限性
- 原文结论指出需进一步研究。
- 原文为大规模回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Role of adjuvant radiation therapy in stage III (N2) non-small cell lung cancer has been controversial over the decades. Recent large, randomized trials have demonstrated that adjuvant radiation did not improve overall survival or disease-free survival; however, the trials either excluded or enrolled very few cases that have undergone neoadjuvant chemotherapy. Role of adjuvant radiation after neoadjuvant chemotherapy remains unclear. Whether the use of adjuvant radiation is associated with improved overall survival in those who have received neoadjuvant chemotherapy, especially in a subgroup of patients with persistent N2, is unknown. MATERIALS AND METHODS: Patients with clinical stage III (N2) non-small cell lung cancer diagnosed from 2004 through 2017 were queried to National Cancer Database. Eligibility criteria included completely resected (R0), pathological diagnosis, neoadjuvant multi-agent chemotherapy, information regarding post-surgical N2 status (persistent versus downstaged to pN0-1), adjuvant radiation (45 Gy+ versus none), and American Joint Commission on Cancer staging version (6th versus 7th). Those who have received neoadjuvant radiation with any dose or adjuvant radiation with less than 45 Gy total dose were excluded. Kaplan-Meier and log-rank tests were used for survival analyses. Propensity-score matching analysis was used for validation. All statistical analyses were two-sided, and p < 0.05 was required for statistical significance. RESULTS: A total of 1,855 patients met the eligibility criteria for analysis. In the overall cohort, there was a significant difference in overall survival between persistent N2 (Cohort P: N = 854, median survival 50.7 months) and downstaged N (Cohort D: N = 1,001, median survival 82.7 months). The use of adjuvant radiation showed a non-significant detrimental effect in overall survival in the overall and Cohort D (univariate p-values 0.27 and 0.077, respectively); however, both univariate and multivariate analyses demonstrated a significant improvement in overall survival in Cohort P (p = 0.004 and 0.028, respectively). These findings are also verified by propensity-score matching analysis (p = 0.0347). CONCLUSIONS: This large-scale retrospective analysis suggests that adjuvant radiation may still have a role in persistent N2 disease after neoadjuvant chemotherapy. Further investigations are warranted.
引用
- Komiya T, Takamori S, Wilding G, et al. Adjuvant radiation therapy improves survival in stage IIIA (N2) non-small cell lung cancer with persistent N2 disease after neoadjuvant chemotherapy. Radiother Oncol. 2022. PMID: 36192229. doi:10.1016/j.radonc.2022.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。